F-star Therapeutics, Inc.
FSTX evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- fs118 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for FSTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
fs118 (Phase 2)
Next Catalyst
—
Tracking 4 pipeline candidates for F-star Therapeutics, Inc..
Run F-star Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available F-star Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is F-star Therapeutics, Inc.'s lead drug candidate?
F-star Therapeutics, Inc.'s most advanced tracked candidate is fs118 (Phase 2) for PD-1/PD-L1 acquired resistance head and neck cancer, CPI-naïve non-small cell lung cancer (NSCLC), and diffuse large B-cell lymphoma (DLBCL).
Who is the CEO of F-star Therapeutics, Inc.?
Eliot Forster is the chief executive officer of F-star Therapeutics, Inc. (FSTX).
What therapeutic areas does F-star Therapeutics, Inc. focus on?
F-star Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.